Research funder · United States
Children's Tumor Foundation
Foundation dedicated to improving the health and well-being of individuals and families affected by neurofibromatosis
- Grants since 2016
- 436
- Awarded, last 5 years (where amounts are published)
- 28.1M
- Funded works, last 5 years
- 115
- Funded works, all time
- 426
Grants
2026 · award
CTF Biorepository
Tatiana Foroud · Indiana University Indianapolis
2026–2028 · award
Inhibition of IL-33 secretion as a therapeutic strategy in schwannomatosis-associated pain
Ran Cao · Regent University
2026–2028 · award
Metabotropic glutamate receptor 7 as a novel modifier and drug target for NF1-related cognitive impairment
Harrison Parent · Vanderbilt University
2026–2028 · award
Development and Use of a Ras-GAP Glue in NF1
Jonathan Chernoff · Fox Chase Cancer Center
2026–2028 · award
Repurposing the Shelved DGAT1 Inhibitor Pradigastat for NF1-Associated Tumors
Daochun Sun · Medical College of Wisconsin
2026–2028 · award
Pharmacologic Inhibition of Cyclin-Dependent Kinases to Treat NF1-Associated MPNST
Colin Beach · Indiana University School of Medicine
2026–2028 · award
Exploring the interplay between UBR5 expression and NF1-MPNST immunogenicity: Implications for immunotherapy
Diana Odhiambo · Washington University in St. Louis
2026 · award
Circular RNA Therapeutics for Neurofibromatosis type 1 (NF1)
Vikas Kumar · Massachusetts General Hospital
2026–2028 · award
Discover Dark Genome Biology and Therapeutic Vulnerabilities in Malignant Peripheral Nerve Sheath Tumor
Mitchell Grinwald · Washington University in St. Louis
2026–2028 · award
A Novel Mechanism of Resistance to MEK Inhibitors in Plexiform Neurofibromas
Alessandro Mauro Mozzarelli · New York University
2026–2028 · award
HEMO as a Biomarker and Target for Malignant Peripheral Nerve Sheath Tumors (MPNST)
David Largaespada · Twin Cities Orthopedics
2026–2028 · award
Longitudinal MRI Radiomic Biomarkers to Assess Treatment Outcomes in Children with NF1-OPG
Zhifan Jiang · Children's National
2026–2027 · award
Pending
Scott Plotkin · Massachusetts General Hospital
2026–2028 · award
Determining the metabolic consequences of PRMT5 inhibition in MTAP-deleted NF1-MPNST to inform therapeutic combinations
Kathryn Lemberg · Johns Hopkins University
2026–2028 · award
Defining clinical trial inclusion criteria and endpoints for scoliosis patients with NF1
Jonathan Rios · Scottish Rite For Children
2026–2028 · award
Targeting MPNST by combining RAS pathway inhibitors with a dual-warhead CoREST complex antagonist
Philip Cole · Brigham and Women's Hospital
2026–2028 · award
Deploying a quantitative multiparametric platform to evaluate metabolic reprogramming as a therapeutic strategy for NF2-related schwannomatosis in vivo.
Andrea I. Mcclatchey · Massachusetts General Hospital
2026–2027 · award
Leveraging Clinical Testing to Establish a Foundational cfDNA Dataset for Neurofibromatosis Type 1 Translational Research
Angela Hirbe · Washington University in St. Louis
2025–2027 · award
Phase II Trial of BMS-0986504, a novel protein arginine methyltransferase 5 (PRMT5) inhibitor, for the treatment of patients with malignant peripheral nerve sheath tumors (MPNST) that are methylthioadenosine phosphorylase (MTAP) deficient
Gary Schwartz · Case Western Reserve University
2025–2027 · award
Metabolomic biomarkers in patients with NF1 and Plexiform Neurofibroma
Miriam Bornhorst · Lurie Children's Hospital
2025–2027 · award
Preclinical testing of calcineurin inhibitor in animal model of Neurofibromatosis type 1 (NF1)
Jay Pundavela · Cincinnati Children's Hospital Medical Center
2025–2026 · award
Orthotopic, regeneration-driven NF2-SWN xenograft mouse model
Lars Björn Riecken · Leibniz Institute on Aging - Fritz Lipmann Institute (FLI)
2025–2028 · award
LNP-Mediated mRNA Therapy in NF2-Related Schwannomatosis (NF2-SWN)
Helen Morrison · Leibniz Institute on Aging - Fritz Lipmann Institute (FLI)
2025–2027 · award
Midbrain circuits contributing to ADHD-like symptoms in NF1 model mice
Zoe Cappel · Cincinnati Children's Hospital Medical Center
2025–2027 · award
Tolerability and Pharmacokinetic/Pharmacodynamic (PK/PD) evaluation, and 12-week experimental therapeutics in vivo efficacy evaluation, of SGR-4174 as a single agent and in combination with Mirdametinib in NF1-associated plexiform neurofibromas.
D. Wade Clapp · Indiana University
2025–2027 · award
Deciphering HMGA2-governed transcriptional networks in NF1-malignant peripheral nerve sheath tumor (MPNST) using integrated multi-omics
Steven Rhodes · Indiana University
2025–2027 · award
Using a novel NF1 brain biomarker to assess therapeutic potential
Daniel Vogt · Michigan State University
2025–2027 · award
Preclinical therapeutic evaluation of systemic chemotherapy regimens in combination with SHP2 inhibitor in NF1-associated malignant peripheral nerve sheath tumors
Lindy Zhang · Johns Hopkins University
2025–2027 · award
Leveraging Spatial, Cell-type Specific Analyses to Decode the Tumor Microenvironment and Advance Therapeutic Strategies for NF1 tumors
Alberto Mendoza Valderrey · University of California, Los Angeles
2025–2027 · award
Decoding Tumor-Associated and Intrinsic Drivers of Cognitive Impairment in NF1 through Integrative Transcriptomics
Rajasekaran Mahalingam · The University of Texas MD Anderson Cancer Center
2025–2027 · award
CCL2-CCR2 axis as tumor growth and hearing loss drivers and therapeutic targets in NF2-related Schwannomatosis
Simeng Lu · Massachusetts General Hospital
2025–2027 · award
Using Cancer Neuroscience approaches to uncover novel targets for malignant peripheral nerve sheath tumors (MPNSTs)
Khalil Ali Ahmad Kasm · The University of Texas MD Anderson Cancer Center
2025 · award
CTF Biorepository
Tatiana Foroud · Indiana University Indianapolis
2025–2026 · award
Validation of AI-Predicted Drug Candidates for Schwannomas
Cristina Fernandez-Valle · The University Of Central Florida Board Of Trustees
2025–2027 · award
Integrating CD200AR-L and Oncolytic Viral Therapy for NF1-Mutated MPNST
Robert Galvin · Twin Cities Orthopedics
2025–2027 · award
Set up of an iPSC-derived Neural Crest-based in vitro/in vivo MPNST pre-clinical platform
Meritxell Carrió
2025–2027 · award
Integration of lipidomics and transcriptomics to evaluate targetable metabolic adaptations in NF1 tumors
Kimani Njoya · Medical College of Wisconsin
2025–2027 · award
The role of the human microenvironment on Neurofibromatosis-related tumor formation and progression
Jonas Van Lent · Fondazione Per L’istituto Oncologico Di Ricerca (ior)
2025–2027 · award
Targeting multidrug resistance (MDR) mechanisms in meningioma (MN) and schwannoma (SW); a novel approach to prevent the challenges posed by drug resistance observed in prior treatment efforts for NF2 patients
Sylwia Ammoun · University of Plymouth
2025–2027 · award
A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]
David Largaespada · Twin Cities Orthopedics